A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

Trial Profile

A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Acronyms EMPHENE
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 8 Oct 2018 to 29 Nov 2018.
    • 19 Jul 2017 Planned primary completion date changed from 8 Oct 2018 to 29 Nov 2018.
    • 19 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top